Low-dose Oral Thimerosal for the Treatment of Oral Herpes: Clinical Trial Results and Improved Outcome After Post-hoc Analysis

BACKGROUND: Thimerosal (TML) is an organomercury antimicrobial. Low doses (1/250(th) of the amount in a typical vaccine dose) may promote an antiviral immune response. Low-dose TML (BTL-TML) was evaluated for safety and efficacy against herpes labialis in two FDA-approved, randomized, double blind,...

Descripción completa

Detalles Bibliográficos
Autores principales: Mamber, Stephen W., Hatch, Thomas, Miller, Craig S., Murray, John V., Strout, Cynthia, McMichael, John
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2022
Materias:
Original Manuscript
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8841908/
https://www.ncbi.nlm.nih.gov/pubmed/35142535
http://dx.doi.org/10.1177/2515690X221078004

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8841908/
https://www.ncbi.nlm.nih.gov/pubmed/35142535
http://dx.doi.org/10.1177/2515690X221078004

Ejemplares similares